BMS-986251 T40123

Product Introduction
Bioactivity


英文名: BMS-986251

描述: BMS-986251 is a potent and specific RORγt inverse agonist that exerts its action via oral administration. It shows an EC 50 of 12 nM for RORγt GAL4. In human whole blood assay, BMS-986251 effectively inhibits IL-17 with an EC 50 of 24 nM. Furthermore, BMS-986251 exhibits strong therapeutic effects in mouse acanthosis and Imiquimod-induced models, which are commonly used preclinical models for psoriasis.

体外活性: BMS-986251 is against ROR family members (RORα GAL4: EC 50 >10 μM; RORβ GAL4: EC 50 >10 μM) and against other nuclear receptors (PXR: EC 50 >5 μM; LXRα: EC 50 >7.5 μM; LXRβ: EC 50 >7.5 μM). BMS-986251 does not inhibit any of the CYP’s[1].

体内活性: BMS-986251 (5-45 mg/kg; orally; twice daily until day 9) results in reduced ear thickness[1]. BMS-986251 (0.13, 0.79, 4.76 mg/kg; orally; once a day) displays a dose-dependent reduction of the IL-17F produced in na?ve C57BL/6 female mice (7-9 weeks)[1]. BMS-986251 (2 mg/kg of IV and 4 mg/kg of PO) has a T 1/2 of 7.7 hours, a CL of 2.7 mL/min?kg, and a V ss of 1.9 L/kg for IV in mouse[1]. Animal Model: C57BL/6 female mice with acanthosis[1]Dosage: 5, 15, 45 mg/kg Administration: Orally; twice daily until day 9 Result: Resulted in reduced ear thickness and significantly reduces imiquimod (IMQ)-induced skin thickening. Animal Model: Mouse or rat[1]Dosage: 2 mg/kg of IV and 4 mg/kg of PO (Pharmacokinetic Analysis) Administration: IV or PO Result: Had a T 1/2 of 7.7 hours, a CL of 2.7 mL/min?kg, and a V ss of 1.9 L/kg for IV in mouse. Had a C max of 4.8 μM and an AUC of 37 μM?h for PO in mouse. Had a T 1/2 of 11 hours, a CL of 1.3 mL/min?kg, and a V ss of 1.25 L/kg for IV in rat. Had a C max of 4.7 μM and an AUC of 64 μM?h for PO in rat.

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

关键字: BMS 986251 | BMS986251 | BMS-986251

BMS-986251 T40123信息由TargetMol中国为您提供，如您想了解更多关于BMS-986251 T40123报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途